News
BIIB
150.38
+2.04%
3.01
Notable Friday Option Activity: BIIB, RBLX, FRPT
NASDAQ · 9h ago
BUZZ- Some defensives outperform, even as indexes switch to gains
Reuters · 10h ago
How Is The Market Feeling About Biogen?
Benzinga · 12h ago
ClearBridge All Cap Growth Strategy Q4 2024 Commentary
Seeking Alpha · 15h ago
SLDB Stock Rallies 60% in a Month: Here's What You Should Know
NASDAQ · 16h ago
Alzheimer's Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding
Benzinga · 1d ago
Biogen (BIIB) Receives a Hold from Bernstein
TipRanks · 1d ago
Genentech : FDA Accepts SBLA For Gazyva For Lupus Nephritis Treatment
NASDAQ · 3d ago
Biogen (BIIB) Receives a Hold from Piper Sandler
TipRanks · 3d ago
Validea Detailed Fundamental Analysis - BIIB
NASDAQ · 4d ago
Eisai and Biogen Announces That The Therapeutic Goods Administration Of Australia Has Confirmed The Initial Decision To Decline The Approval Of Humanized Anti-Soluble Aggregated Amyloid-Beta Monoclonal Antibody Lecanemab As A Treatment For Early Alzheimer's Disease
Benzinga · 4d ago
Eisai, Biogen announce TGA of Australia declined approval of lecanemab
TipRanks · 4d ago
Weekly Report: what happened at BIIB last week (0224-0228)?
Weekly Report · 4d ago
3 Reasons BIIB is Risky and 1 Stock to Buy Instead
Barchart · 5d ago
BIOGEN INC. ANNUAL REPORT ON FORM 10-K For the Year Ended December 31, 2024
Press release · 5d ago
Play defense with Goldman's cheap healthcare picks
Seeking Alpha · 5d ago
Denali Q4 Earnings Beat Estimates, Hunter Syndrome Drug in Focus
NASDAQ · 02/28 18:14
Biogen (NasdaqGS:BIIB) Awaits EU Decision On Lecanemab After CHMP Reaffirms Positive Opinion
Simply Wall St · 02/28 17:19
Biogen, Eisai: CHMP Reaffirms Backing of Leqembi Alzheimer's Drug
Dow Jones · 02/28 14:52
Biogen, Eisai Alzheimer’s drug sent back for EU nod after safety review
Seeking Alpha · 02/28 14:06
More
Webull provides a variety of real-time BIIB stock news. You can receive the latest news about Biogen Inc through multiple platforms. This information may help you make smarter investment decisions.
About BIIB
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).